A Cohort Study to Compare Effects between Ulcer- and Nonulcer-Related Nonvariceal Upper Gastrointestinal Bleeding

Bi Nian1, Bangping Wang1, Long Wang2

  • 1Department of Gastroenterology, Suzhou First People's Hospital, China.

Insights

Peptic ulcers are the leading cause of acute nonvariceal upper gastrointestinal bleeding (ANVUGIB). NSAID use is a major trigger in the elderly, while lifestyle factors affect younger patients more.

Area of Science:

  • Gastroenterology
  • Internal Medicine
  • Clinical Research

Background:

  • Acute nonvariceal upper gastrointestinal bleeding (ANVUGIB) is a significant clinical concern.
  • Understanding regional characteristics and etiology is crucial for evidence-based management.

Purpose of the Study:

  • To investigate the epidemiological characteristics and etiological factors of ANVUGIB.
  • To analyze age-related differences in ANVUGIB causes and triggers.
  • To provide updated medical evidence for clinical practice.

Main Methods:

  • Retrospective analysis of 100 ANVUGIB patients admitted between January 2017 and December 2021.
  • Patients categorized into young (18-39), middle-aged (40-59), and elderly (60+).
  • Etiology confirmed via endoscopy; data analyzed using SPSS 23.0.

Main Results:

  • Peptic ulcers were the primary cause of ANVUGIB.
  • Gastric ulcers predominated in the elderly, while duodenal ulcers were more common in younger groups.
  • NSAID use was a significant trigger in the elderly, unlike younger demographics where lifestyle factors were more prevalent.

Conclusions:

  • Peptic ulcer disease remains the most frequent cause of ANVUGIB.
  • Acute gastric mucosal lesions and upper digestive system tumors are less common causes compared to ulcers.
  • Age-specific etiological factors and triggers necessitate tailored clinical approaches.
Abstract

Related Concept Videos

Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
280
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
193
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
811
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
680
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
131
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
594